SCHEMBL20437163

SCHEMBL20437163

Cc1ccc(S(=O)(=O)n2ccc3c(Oc4ccc(C[C@H](NC(=O)OC(C)(C)C)C(=O)Nc5ccccc5)cc4F)ccnc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC8 Q9BY41 1/20 0.43
NTRK1 P04629 1/20 0.39
MET P08581 2/20 0.38
KLK7 P49862 1/20 0.38
BCL2 P10415 5/20 0.38
SCN9A Q15858 2/20 0.37
ALDH1A1 P00352 1/20 0.37
TSHR P16473 1/20 0.37
PTPN1 P18031 2/20 0.37
CCKAR P32238 2/20 0.36
CCKBR P32239 2/20 0.36
CTSS P25774 2/20 0.36
CTSK P43235 2/20 0.36
CYP3A4 P08684 1/20 0.36
CTSB P07858 1/20 0.36
MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23799314 0.91 MEN1 (0.48) MEN1POLBKMT2AMETKLK7
SCHEMBL23799313 0.91 MEN1 (0.48) MEN1POLBKMT2AMETKLK7
SCHEMBL21626648 0.89 MEN1 (0.43) MEN1POLBKMT2AMETBCL2
SCHEMBL20437159 0.89 HDAC8 (0.42) MEN1POLBKMT2AHDAC8NTRK1
SCHEMBL20437165 0.89 HDAC8 (0.42) MEN1POLBKMT2AHDAC8NTRK1
SCHEMBL20437166 0.87 MEN1 (0.41) MEN1POLBKMT2AMETKLK7
SCHEMBL23072680 0.87 MEN1 (0.41) MEN1POLBKMT2AMETKLK7
SCHEMBL23072645 0.86 HDAC8 (0.42) HDAC8NTRK1METSCN9APTPN1
SCHEMBL21593064 0.83 MET (0.40) MEN1POLBKMT2AMET
SCHEMBL20422614 0.81 MET (0.38) POLBMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10954236-B2 Tyrosine amide derivatives as Rho-Kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2021-03-23 US disclosed
EP-3573987-B1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARM SPA (IT) 2021-03-10 EP disclosed
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2018-08-02 US disclosed
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2018-08-02 US disclosed
WO-2018138293-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2018-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10954236-B2 Tyrosine amide derivatives as Rho-Kinase inhibitors ROCK1, ROCK2, CIT MEN1 4596/4885POLB 2905/4885KMT2A 1361/4885
US-20180215758-A1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, CIT MEN1 4596/4885POLB 2905/4885KMT2A 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.